Comprehensive Analysis Identifies THEMIS2 as a Potential Prognostic and Immunological Biomarker in Glioblastoma
Cells · 2025
DOI: 10.3390/cells14020066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Jianan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, Moffitt Cancer Center Foundation.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by its ability to evade the immune system, hindering the efficacy of current immunotherapies. Recent research has highlighted the important role of immunosuppressive macrophages in the tumor microenvironment (TME) in driving this immune evasion. In this study, we are the first to identify THEMIS2 as a key regulator of tumor-associated macrophage (TAM)-mediated immunosuppression in GBM. We found that a high THEMIS2 expression is associated with poor patient outcomes and increased infiltration of immune cells, particularly macrophages. Functional analyses revealed THEMIS2’s critical involvement in immune-related pathways, including immune response activation, mononuclear cell differentiation, and the positive regulation of cytokine production. Additionally, single-cell RNA sequencing data demonstrated that macrophages with a high THEMIS2 expression were associated with increased phagocytosis, immune suppression, and enhanced tumor growth. These findings suggest that THEMIS2 could serve as both a prognostic marker and a therapeutic target for enhancing anti-tumor immunity in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
- Departments of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
ORCID-Profile: Jianan Chen, Qiong Wu, Anders E Berglund, Robert J Macaulay, Arnold B Etame
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- Moffitt Cancer Center Foundation
- National Institute of Neurological Disorders and Stroke
- National Cancer Institute
Zitieren
APA
Chen, J., Wu, Q., Berglund, A. E., Macaulay, R. J., & Etame, A. B. (2025). Comprehensive Analysis Identifies THEMIS2 as a Potential Prognostic and Immunological Biomarker in Glioblastoma. Cells. https://doi.org/10.3390/cells14020066
Vancouver
Chen J, Wu Q, Berglund AE, Macaulay RJ, Etame AB. Comprehensive Analysis Identifies THEMIS2 as a Potential Prognostic and Immunological Biomarker in Glioblastoma. Cells. 2025. doi:10.3390/cells14020066
BibTeX
@article{Chen2025,
author = {Chen, Jianan and Wu, Qiong and Berglund, Anders E and Macaulay, Robert J and Etame, Arnold B},
title = {Comprehensive Analysis Identifies THEMIS2 as a Potential Prognostic and Immunological Biomarker in Glioblastoma},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14020066}
}
EUVIMED